Advances of anti-inflammation therapy targeting ApoB-100 against atherosclerosis
10.3969/j.issn.1674-8115.2018.09.017
- Author:
Xiao-Yu GUO
1
Author Information
1. Department of Anesthesiology and SICU, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Publication Type:Journal Article
- Keywords:
ApoB-100;
Atherosclerosis (AS);
Immunization;
Inhibitor;
Vaccine
- From:
Journal of Shanghai Jiaotong University(Medical Science)
2018;38(9):1104-1108
- CountryChina
- Language:Chinese
-
Abstract:
Atherosclerosis is an inflammatory disease of arterial wall caused by many factors, which is the main pathological basis of many cardiovascular diseases. Currently, "inflammatory response" theory is widely accepted as pathogenesis of atherosclerosis. Abnormal increase of apolipoprotein ApoB-100, a composition of low density lipoprotein (LDL), which causes pathological inflammation, is a major factor leading to atherosclerosis. Therefore, inhibition of ApoB-100 induced pathological inflammatory response by immunotherapy is expected to delay the development of atherosclerosis. This review focused on the recent advances of ApoB-100 vaccine and other ApoB-100 inhibitors against atherosclerosis.
